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Abstract
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder causing motor and non-motor
symptoms that can affect independence, social adjustment and the quality of life (QoL) of both patients and caregivers.
Studies designed to find diagnostic and/or progression biomarkers of PD are needed. We describe here the study
protocol of COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), an integral PD project based
on four aspects/concepts: 1) PD as a global disease (motor and non-motor symptoms); 2) QoL and caregiver issues; 3)
Biomarkers; 4) Disease progression.
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Methods/design: Observational, descriptive, non-interventional, 5-year follow-up, national (Spain), multicenter (45
centers from 15 autonomous communities), evaluation study. Specific goals: (1) detailed study (clinical evaluations,
serum biomarkers, genetic studies and neuroimaging) of a population of PD patients from different areas of Spain, (2)
comparison with a control group and (3) follow-up for 5 years. COPPADIS-2015 has been specifically designed to assess
17 proposed objectives. Study population: approximately 800 non-dementia PD patients, 600 principal caregivers and
400 control subjects. Study evaluations: (1) baseline includes motor assessment (e.g., Unified Parkinson’s Disease Rating
Scale part III), non-motor symptoms (e.g., Non-Motor Symptoms Scale), cognition (e.g., Parkinson’s Disease Cognitive
Rating Scale), mood and neuropsychiatric symptoms (e.g., Neuropsychiatric Inventory), disability, QoL (e.g., 39-item
Parkinson’s disease Quality of Life Questionnaire Summary-Index) and caregiver status (e.g., Zarit Caregiver Burden
Inventory); (2) follow-up includes annual (patients) or biannual (caregivers and controls) evaluations. Serum biomarkers
(S-100b protein, TNF-α, IL-1, IL-2, IL-6, vitamin B12, methylmalonic acid, homocysteine, uric acid, C-reactive protein,
ferritin, iron) and brain MRI (volumetry, tractography and MTAi [Medial Temporal Atrophy Index]), at baseline and at
the end of follow-up, and genetic studies (DNA and RNA) at baseline will be performed in a subgroup of subjects (300
PD patients and 100 control subjects). Study periods: (1) recruitment period, from November, 2015 to February, 2017
(basal assessment); (2) follow-up period, 5 years; (3) closing date of clinical follow-up, May, 2022. Funding: Public/Private.
Discussion: COPPADIS-2015 is a challenging initiative. This project will provide important information on the natural
history of PD and the value of various biomarkers.
Keywords: Biomarkers, Caregiver, Genetic studies, Magnetic resonance imaging, Non-motor symptoms, Parkinson’s
disease, Progression, Quality of life
Background
Parkinson’s disease (PD), the second most common neu-
rodegenerative disease after Alzheimer’s disease, is a pro-
gressive neurodegenerative disorder causing motor and
non-motor symptoms that result in disability, loss of pa-
tient autonomy and caregiver burden [1]. Understanding
of PD has changed over recent years, with the disease
currently considered to be a neurodegenerative disease
involving a diversity of pathways and neurotransmitters
that may explain, in part, the large range of symptoms
that patients may have [2]. PD is not only a motor dis-
ease, as it also involves various non-motor symptoms
that are important for different reasons. Non-motor
symptoms are frequent and disabling, therefore, early
identification and proper management of these symp-
toms is important [3]. Some non-motor symptoms (e.g.,
olfactory disorders, constipation or sleep disturbances)
may precede motor symptoms, and could be useful as
prodromal/preclinical markers of PD [4]. Others, such
as dementia and psychosis, are more frequently develop
during the late stages of the disease and sometimes dif-
ficult to manage. We need to know, in detail, the pro-
gression of non-motor symptoms and their relationship
with motor changes over time. Reliable and well-
validated biomarkers for PD to identify individuals “at
risk” before motor symptoms develop, to accurately
diagnose individuals at the threshold of clinical PD, and
to monitor PD progression (motor and non-motor
symptoms) throughout the course of the disease would
dramatically accelerate research into both the cause
and treatment of PD [5].
Although the identification of a marker for diagnosis
and for disease progression (preferably one that is non-
invasive, affordable and accessible) is of utmost import-
ance, concepts like quality of life (QoL) are also very
important in chronic diseases, such as PD, for which a
cure does not exist [6]. Improving patient QoL and iden-
tifying factors that lead to caregiver burden are very im-
portant aspects of the management of PD. In particular,
the role of the principal caregiver in PD is very import-
ant because caregiver burden generates poor care and, in
the long term, leads to patient institutionalization [7].
Specifically, identifying the changes experienced by PD
patients and their caregivers in their QoL and degree of
burden, respectively, over time, as well as factors that
may predict these changes, in order to carry out a
proper intervention, should be a priority. Well-designed,
longitudinal prospective studies are key. Access to a
population with a high proportion of patients who have
been assessed comprehensively and rigorously, without
screening bias, is highly valuable for both cross-sectional
analysis and prospective follow-up. This is especially
relevant for studying populations affected by a neurode-
generative disease, given that these patients are expected
to develop different complications that we could identify
and analyze.
Studies designed to identify PD diagnostic and/or pro-
gression biomarkers and to elucidate the natural pro-
gression of the disease are needed. We describe here the
COPPADIS-2015 (COhort of Patients with PArkinson’s
DIsease in Spain, 2015) study protocol, an integral PD
project based on four aspects/concepts: 1) PD as a global
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disease (motor and non-motor symptoms); 2) QoL and
caregiver issues; 3) Biomarkers; 4) Disease progression.
Methods/design
Type of study
COPPADIS-2015 is a national, multicenter, epidemio-
logical, descriptive, observational, non-interventional,
longitudinal-prospective, 5-year follow-up study. COPP
ADIS-2015 has been classified by the AEMPS (Agencia
Española del Medicamento y Productos Sanitarios) as a
Post-authorization Prospective Follow-Up study.
The study will be conducted at different hospital sites
in Spain. The essential requirement will be that the
Principal Investigator participating at each site has ex-
perience and skills in the diagnosis and standard man-
agement of patients with PD in their daily clinical
practice. As such, the participating site could be any es-
tablishment from a highly-specialized Movement Disor-
ders Unit of a tertiary hospital to a general neurologist
from a regional hospital with the aforementioned skills.
More than one hundred researchers from 48 centers in
Spain, from 15 autonomous communities, will partici-
pate in this project.
Specific goals
The aim COPPADIS-2015 is to: (1) study in detail
(clinical evaluations, serum biomarkers, genetic studies
and neuroimaging) a population of patients with PD
representative of different areas of Spain; (2) compare it
with a control group and (3) follow-up for 5 years.
COPPADIS-2015 has been specifically designed to assess
17 proposed objectives (Table 1).
Study population
Non-dementia patients with idiopathic PD, caregivers
(patient’s primary caregiver, if applicable) and controls
will be assessed. We plan to include:
1) Approximately 800 patients with PD. Patients will
be included if they have idiopathic PD according to the
United Kingdom Parkinson’s Disease Society Brain Bank
Table 1 Specific objectives of the COPPADIS-2015 project
1) To study what variables (non-motor symptoms, cognition, neuropsychiatric symptoms, falls, disability, etc.) impact negatively on both overall and
health-related QoL of patients with PD.
2) To study what variables contribute to a worse QoL, mood and the burden of the primary caregiver for the patient with PD, as well as if the
latter have repercussions on the mood and QoL of the patient him/herself.
3) To study the frequency of impulse control disorders and their types in patients with PD, as well as what variables are associated with them and
to compare it against a control group.
4) To study the frequency of different non-motor symptoms in patients with PD and to compare it against a control group.
5) To study the frequency of pain (and its types) [90] in patients with PD, its relationship to the disease and different variables and to compare it
against a control group.
6) To study the frequency of different types of mood disorders (major depression, minor depression, subclinical depression) [91, 92] in patients
with PD, its relationship with other disease variables and to compare it against a control group.
7) To study the different types of parkinsonian phenotypes [93, 94] and their relationship with other variables (clinical, molecular, genetic and
neuroimaging).
8) To study the relationship between different variables (clinical, molecular, genetic and neuroimaging) and motor laterality asymmetry [95].
9) To study the relationship between the serum levels of S-100b protein, TNF-ɑ, IL-1, IL-2, IL-6, vitamin B12, methylmalonic acid, homocysteine, uric
acid, C-reactive protein, ferritin and iron and other disease variables in patients with PD and to compare it against a control group.
10) To perform genetic studies on DNA and RNA extracted from the lymphocytes of peripheral blood samples.
11) To study the possible value of a recently proposed imaging marker (MTAi) [30] to detect cognitive alterations in patients with PD and to
compare it against a control group.
12) To perform volumetric imaging and tractography studies to find correlations, under plausible hypotheses, between the neuroimaging
parameters and the clinical or neuropsychiatric variables and/or other variables covered in this study [59–61].
13) To study the incidence of acute hospitalization throughout the 12 months following the baseline assessment (for each patient), their causes, and
predictive factors in patients with PD and to compare it against a control group.
14) To study what percentage of patients with PD develop motor complications (in the subgroup of those who do not present them at the
baseline assessment) throughout the 48 months following the baseline assessment (for each patient) and to identify predictive factors.
15) To study what percentage of patients with PD develop significant cognitive impairment and/or dementia over the course of the 24, 48 and
60 months following the baseline assessment (for each patient), to compare it against a control group and to identify predictive factors (clinical,
molecular, genetic, imaging).
16) To study the morbidity and mortality of patients with PD throughout the 24 and 60 months following the baseline assessment (for each
patient), to compare it against a control group and to identify predictive factors (clinical, molecular, genetic, imaging).
17) At the end of follow-up, to compare the course of the different clinical (motor and no-motor features) and paraclinical variables (molecular and
imaging markers).
IL interleukin, PD parkinson’s disease, MTAi, medial temporal atrophy index, QoL quality of life, TNF tumor necrosis factor
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criteria [8], have no dementia criteria (Mini Mental State
Examination [MMSE] ≥ 26) [9], are aged between 30 and
75 years, are participating voluntarily and have provided
written informed consent. Patients will be excluded from
the study if they: (1) are not capable of completing the
questionnaires adequately; (2) have other disabling con-
comitant neurological disease (stroke, severe head
trauma, neurodegenerative disease, etc.); (3) have other
severe and disabling concomitant non-neurological dis-
ease (oncological, autoimmune, etc.); (4) have known
chronic anemia and/or hyperuricemia; (5) are receiving
active treatment with continuous infusion of levodopa
and/or apomorphine and/or with deep brain stimulation;
(6) they are participating in a clinical trial and/or other
type of study that does not permit concomitant partici-
pation in another or (7) if long-term follow-up is not
expected to be possible.
2) Approximately 600 caregivers (patient’s primary
caregiver). A person who, without being a professional
and/or receiving money in exchange for services, lives
with the patient and is responsible for his/her care will
be included as a primary caregiver [10]. He or she must
voluntarily agree to participate and provide written in-
formed consent.
3) Approximately 400 control subjects matched by
age, sex and educational level. The control subject
could be a family member (not the patient’s caregiver)
or friend of the patient who would like to participate
voluntarily. The same inclusion criteria (except PD
diagnosis) and exclusion criteria as those for the pa-
tients will be applied.
Study design
The study will be carried out in two phases:
1) Cross-sectional assessment (recruitment of patients
with a baseline assessment over a period of
16 months, from November 2015 to February 2017).
We have also considered the possibility, if necessary,
of extending the recruitment period up to a
maximum of 24 months in order to achieve the
proposed target sample size.
2) Prospective follow-up of the defined cohort of PD
patients (COPPADIS) over 5 years.
Study assessments
The Principal Investigator will make the decision on the
patient’s inclusion. Extensive information on sociodemo-
graphic aspects, factors related to PD, comorbidity and
treatment will be collected. Patient baseline evaluations
will include motor assessment (Hoenh & Yahr [11], Uni-
fied Parkinson’s Disease Rating Scale [UPDRS] part III
and part IV [12], Freezing of Gait Questionnaire [FOGQ]
[13]), non-motor symptoms (Non-Motor Symptoms Scale
[NMSS] [14], Parkinson’s Disease Sleep Scale [PDSS]
[15], Visual Analog Scale-Pain [VAS-Pain] [16], Visual
Analog Fatigue Scale [VAFS] [17]), cognition (MMSE
[18], Parkinson’s Disease Cognitive Rating Scale [PD-
CRS] [19], completing a simple 16-piece puzzle [20]),
mood and neuropsychiatric symptoms (Beck Depression
Inventory-II [BDI-II] [21], Neuropsychiatric Inventory
[NPI] [22], Questionnaire for Impulsive-Compulsive
Disorders in Parkinson’s Disease-Rating Scale [QUIP-RS]
[23]), disability (Schwab & England Activities of Daily
Living Scale [ADLS] [24]) and QoL (39-item Parkinson’s
disease Quality of Life Questionnaire Summary Index
[PDQ-39SI] [25], PQ-10 [26], European Health Interview
Survey-Quality of Life 8 item index [EUROHIS-QOL 8
item-index] [27]). Caregiver baseline evaluation includes
the degree of burden (Zarit Caregiver Burden Inventory
[ZCBI] [28], Caregiver Strain Index [CSI] [29]), mood
(BDI-II) and QoL (PQ-10, EUROHIS-QOL 8 item-
index). The same evaluation as for the patients, except
for the motor assessment, will be performed in control
subjects at baseline.
In a subgroup of 400 consecutive non-selected sub-
jects (300 PD patients and 100 controls) willing to par-
ticipate voluntarily and without any contraindications
(e.g., magnetic resonance imaging [MRI]), complemen-
tary tests will be performed as follows:
1) Blood sample collection for the determination of
different molecular biomarkers: S-100b protein,
tumor necrosis factor (TNF)-ɑ, interleukin (IL)-1,
IL-2, IL-6, vitamin B12, methylmalonic acid, homo-
cysteine, uric acid, C-reactive protein, ferritin and
iron. The analysis will be conducted at a common
laboratory: REFERENCE LABORATORY (www.re-
ference-laboratory.es). The extraction of the sample
will be carried out no longer than 3 months after
the first clinical assessment.
2) Blood sample collection for genetic studies on
lymphocyte DNA and RNA with 4 fundamental
objectives: (1) expression profile studies; (2) exome
sequencing (SNCA, LRRK2, FBXO7, PINKI, PRKN,
DJ1, HTRA2, UCHLI, ATPI3A2, VPS35, PLA2G6,
GIGYF2, EIF4G1, GBA); (3) analysis of genes
considered relevant according to the state of the art;
(4) candidate gene association studies in order to
determine if the pathological variations are present
more frequently in subjects with PD (with respect to
the control group).
3) Neuroimaging study: T1 3D MRI of the head using
standardized protocols that include frontal and/or
coronal slices in T1 sequence at 1.5 T or above
without intravenous contrast. Volumetric (spoiled
gradient recalled sequence; TR 8,5 ms, TE 4 ms,
flip angle 8°, FOV 240 × 240 mm2, thickness
Santos-García et al. BMC Neurology  (2016) 16:26 Page 4 of 14
1 mm, matrix 288 × 288, voxel size 0.84 mm3)
and tractography (echo-planar imaging; TR
9.500 ms, TE 73 ms, FOV 224, thickness 2 mm,
matrix 128 × 128, b-factors of zero and 700 s/
mm2) studies will be performed. Also, the Medial
Temporal Atrophy Index (MTAi) [30] will be
calculated. The MRI study will be performed no
longer than 6 months after the first clinical
assessment.
Figure 1 shows baseline study assessments. Table 2
shows data regarding centers, number of patients that
they have estimated to recruit and distribution of pa-
tients selected for the complementary studies according
to the different centers.
During the 5 years of follow-up, annual evaluations
(PD patients) or evaluations at 24, 48 and 60 months
(caregivers and controls) will be performed. Figure 2
shows assessments during the follow-up phase in each
group. The subjects who undergo complementary tests
at baseline will repeat the head MRI study (preferably at
the same site and with the same machine) and determin-
ation of molecular markers (S-100b, TNF-ɑ, IL-1, IL-2,
IL-6, vitamin B12, methylmalonic acid, homocysteine,
uric acid, C-reactive protein, ferritin and iron; same la-
boratory, REFERENCE LABORATORY) at 60 months.
Table 3 shows the working plan summary.
Data collection and statistical analysis
Data will be collected using an electronic Case Report
Form (e-CRF) and will be transferred to a statistical
package for subsequent analysis. The company re-
sponsible for study monitoring is Alphabioresearch
(www.alphabioresearch.com).
We calculated the sample size, taking into account a
maximum estimated loss to follow-up of 10 % of pa-
tients per year, and that between 15 % and 20 % of the
sites involved in a multicenter study are estimated to
leave the study for different reasons [31]. A minimum of
280 patients at the end of follow-up would be sufficient
to include up to 27 predictive variables in the multiple
regression analyses with a power of 0.8 and a confidence
a b c
Fig. 1 Recruitment period, from November 2015 to February 2017 (baseline assessment of each participating subject). 1, patient inclusion process
and motor assessment by the Principal Investigator (neurologist who is an expert in movement disorders and Parkinson’s disease); 2a, non-motor
assessment by the Principal Investigator, specialized nurse, psychologist or fellow with adequate training; 2b, caregiver assessment; 2c, control
assessment. *Only patients with motor fluctuations (UPDRS-IV) will be assessed during the OFF-medication (first thing in the morning
without taking medication in the 12 previous hours) and during the ON-medication state; the rest will only be assessed during the OFF-
medication state. Blood samples from the baseline assessment will be stored for the purpose of being able to test other future markers
not currently included in the project
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Table 2 Centers, number of patients that they have estimated to recruit and distribution of patients selected for the complementary
studies according to the different centers






1. Diego Santos García; Neurology Section, Hospital Arquitecto Marcide, Complejo




2. (1) Oriol de Fábregues-Boixar Nebot and (2) Jorge Hernández Vara; Movement






3. Carmen Borrue Fernández; Movement Disorders Unit, Neurology Service, Hospital
Infanta Sofía.
Madrid 50 10 NO
4. Pablo Mir Rivera; Movement Disorders Unit, Neurology and Clinical Neurophysiology
Service, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío,
CSIC and Universidad de Sevilla.
Seville 40 10 40/0
5. Maria José Martí Domenech; Parkinson’s and Movement Disorders Unit, Neurology
Service, Instituto Clínico de Neurociencias, Hospital Clínic.
Barcelona 40 10 NO
6. Miquel Aguilar Barberá; Movement Disorders Unit, Hospital Universitario Mutua de
Terrassa.
Barcelona 40 10 30/10
7. Beatriz Tijero Merino; Functional Neurology and Parkinson’s Disease Unit, Hospital de
Cruces.
Bilbao 35-40 10 NO
8. José Chacón Peña; Neurology Unit, Hospital Infanta Luisa. Seville 30-35 10 NO







10. Víctor Puente Périz; Movement Disorders Unit, Neurology Service, Hospital del Mar. Barcelona 25-30 10 20/10
11. Inés Legarda Ramiréz; Neurology Service, Hospital Universitario Son Espases. Palma de
Mallorca
25 10 NO
12. Francisco Carrillo Padilla; Neurology Service, Hospital Universitario de Canarias, San




13. Lydia López Manzanares; Movement Disorders Unit, Neurology Service, Hospital La
Princesa.
Madrid 25 10 NO
14. Caridad Valero Merino; Neurology Unit, Hospital Arnau de Vilanova. Valencia 20-25 10 NO
15. Jaime Kulisevsky Bojarski; Movement Disorders Unit, Neurology Service, Hospital de
Sant Pau.
Barcelona 20 10 NO
16. José Manuel García Moreno; Movement Disorders Unit, Hospital Universitario Virgen
Macarena.
Seville 20 10 20/10
17. Benito Galeano Bilbao; Neurology Section, Hospital Universitario de Ceuta. Ceuta 20-25 10 20/0





19. Mari Cruz Rodríguez Oroz; Hospital Universitario Donostia, Instituto de Investigación
Biodonostia.
San Sebastián 20 10 20/10
20. María Iciar Gastón Zubimendi; Movement Disorders Unit, Neurology Service,
Complejo Hospitalario de Navarra.
Pamplona 20 10 NO
21. Pilar Sánchez Alonso; Neurology Service, Hospital Puerta de Hierro. Madrid 15-25 10 NO
22. Esther Cubo Delgado; Neurology Service, Complejo Asistencial Universitario de
Burgos.
Burgos 15 10 NO
23. Lydia Vela Desojo; Neurology Unit, Fundación Hospital de Alcorcón. Alcorcón
(Madrid)
15 10 NO
24. Maria José Catalán Alonso; Movement Disorders Unit, Neurology Service, Hospital
Clínico San Carlos.
Madrid 15 10 NO
25. Luis Manuel López Díaz; Neurology Section, Hospital de Burela. Burela (Lugo) 15 10 NO
26. Maria Gema Alonso Losada; Neurology Service, Hospital Meixoeiro, Complejo




27. Nuria López Ariztegui; Movement Disorders Unit, Complejo Hospitalario de Toledo. Toledo 15 10 NO
28. Mónica Kurtis Urra; Movement Disorders Unit, Neurology Service, Hospital Ruber
Internacional.
Madrid 15 10 NO
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interval of 95 % [32]. The pertinent analysis (descriptive
studies, univariate studies, binary logistic regression,
multiple linear regression, etc.) will be performed based
on the type of objective. In addition, given de complexity
of potential analysis including a diversity of variables
from different origin and measurement properties, ad-
vanced statistical methodology (data mining, artificial
intelligence techniques, etc.) will be applied as needed.
One of the authors (PMM) will coordinate these aspects.
Ethical considerations
The project will be conducted in accordance with the
standards for Good Clinical Practice, the fundamental
ethical principles established in the Declaration of
Helsinki and the Oviedo Convention, as well as the re-
quirements established in Spanish legislation in the re-
search field. Approval of the Ethics Committee at each
center was obtained.
Study timetable
1) Pre-start-up procedures: until October 2015.
2) First assessment (cross-sectional assessment):
November 2015 to February 2017.
3) Database review: March–June 2017.
4) Statistical analysis: second half of 2017.
5) Reporting and publication of papers (objectives 1 to
12 of the cross-sectional assessment and other suba-
nalyses): years 2017 to 2019.
6) Objectives of the prospective follow-up of the co-
hort: from 2018 onwards.
Future possibilities of the project
1) To perform other evaluations and/or
complementary studies during follow-up; for ex-
ample, electromyographic studies to determine the
Table 2 Centers, number of patients that they have estimated to recruit and distribution of patients selected for the complementary
studies according to the different centers (Continued)
29. Jon Infante Ceberio; Movement Disorders Unit, Neurology Service, Hospital
Universitario Marqués de Valdecilla.
Santander 15 10 15/10





31. Juan Carlos Martínez Castrillo; Movement Disorders Unit, Neurology Service, Hospital
Ramón y Cajal.
Madrid 15 10 NO
32. José Matías Arbelo González; Movement Disorders and Parkinson’s Disease Unit,




33. René Ribacoba Montero; Movement Disorders Unit, Neurology Service, Hospital
Central de Asturias.
Oviedo 15 10 15/10
34. Jessica González Ardura; Neurology Service, Hospital Universitario Lucus Augusti
(HULA).
Lugo 15 10 NO
35. Javier López del Val; Movement Disorders Unit, Neurology Service, Hospital Clínico
Universitario Lozano Blesa.
Zaragoza 15 10 NO
36. María Asunción Ávila Rivera; Movement Disorders Unit, Consorci Sanitari Integral,




37. Hortensia Alonso Navarro; Neurology Section, Hospital Universitario del Sureste,
Madrid.
Madrid 15 10 NO
38. Berta Solano Vila; Neurology Service, Hospital Josep Trueta and Parc Martí i Juliá,
Girona.
Girona 15 10 NO
39. Juan García Caldentey; Neurology Unit, Hospital Quirón Palmaplanas. Palma de
Mallorca
15 10 NO
40. Ana Rojo Sebastián; Parkinson’s and Abnormal Movement Unit, Neurology Service,





41. Silvia Martí Martínez; Neurology Service, Hospital General de Alicante. Alicante 15 10 NO
42. José Andrés Domínguez Morán; Neurology Unit, Hospital de la Rivera. Alcira (Valencia) 15 10 NO
43. Irene Martínez Torres; Movement Disorders Unit, Neurology Service, Hospital La Fe. Valencia 15 10 NO
44. María Álvarez Sauco; Neurology Service, Hospital General Universitario de Elche. Elche (Alicante) 15 10 NO
45. Cristina Prieto Jurczynska; Movement Disorders Unit, Hospital Infanta Elena-Hospital
Rey Juan Carlos-Hospital Collado Villalba, Madrid.
Madrid 15 10 NO
1.000 470 300/100
PDP parkinson’s disease patient, CS control subject
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frequency of polyneuropathy in PD patients com-
pared with controls and also to identify related risk
factors (clinical, biomarkers, etc.); other studies (op-
tical coherence tomography, electroencephalogram,
salivary secretion and/or cerebrospinal fluid analysis,
skin biopsy, etc.).
2) To continue follow-up of the subjects (patients,
caregivers and controls) over time (10, 15,
20 years, etc.).
3) To create a COPPADIS Brain Bank. We have
designed a working group with the participation of
members of different biobanks in Spain with the aim
of create a Brain Donation Program for COPPADIS
PD patients.
Discussion
The described project, COPPADIS-2015 (COhort of
Patients with PArkinson’s DIsease in Spain, 2015), is an
ambitious initiative that will provide important informa-
tion regarding the natural history of PD and the value of
various biomarkers. The large sample size, high level of
participation, with more than 40 Spanish centers in-
volved, exhaustive clinic evaluations, including motor
and non-motor features (more than 500 variables col-
lected from the baseline assessment), biomarkers, study
design and interesting future possibilities are strong
points of this project. COPPADIS-2015 will enable us to
identify different complications that develop over time
in a very large population of patients with PD. There-
fore, we expect to be able to identify the incidence of
different problems, their impact on QoL and predictive
factors that will allow us to identify these problems early
in order to act.
This project is based on four aspects/concepts: 1) PD
as a global disease (motor and non-motor symptoms); 2)
QoL and caregiver issues; 3) Biomarkers; 4) Disease
progression. For years, PD management was focused on
motor symptoms. However, more recently, non-motor
features have been gaining in importance. Non-motor
symptoms are important for different reasons [33]: they
are frequent and disabling; some non-motor symptoms




Fig. 2 Follow-up of the cohort of patients (a), caregivers (b) and controls (c). At the end of follow-up, the patients (n = 300) and controls (n = 100) who
underwent complementary tests at baseline will undergo repeat testing (molecular markers and imaging study). ADLS, Schwab & England Activities of Daily
Living Scale; BDI, Beck Depression Inventory; CSI, Caregiver Strain Index; FOGQ, Freezing of Gait Questionnaire; HY, Hoenh & Yahr; NMSS, Non-Motor
Symptoms Scale; NPI, Neuropsychiatric Inventory; PD-CRS, Parkinson’s Disease Cognitive Rating Scale; PDQ-39SI, 39-item Parkinson’s disease
Quality of Life Questionnaire Summary Index; QUIP-RS, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale;
PDSS, Parkinson’s Disease Sleep Scale; UPDRS, Unified Parkinson’s Disease Rating Scale; VAFS, Visual Analog Fatigue Scale; VAS-Pain, Visual
Analog Scale-Pain; ZCBI, Zarit Caregiver Burden Inventory
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sleep behavior disorders can precede motor symptoms
and, in the future, such symptoms could be used to es-
tablish an earlier diagnosis of premotor PD; non-motor
symptoms can sometimes be difficult to manage (ortho-
static hypotension, behavioral disorders, etc.); some non-
motor symptoms (dementia, psychosis, etc.) increase the
risk of institutionalization and generate a high economic
cost; and they are not always sufficiently recognized by
the neurologist. Additionally, various studies have dem-
onstrated that non-motor symptoms impact negatively
on patient QoL, and that by improving these symptoms,
we help improve QoL [34, 35]. Early identification and
proper management should currently be a priority in
daily clinical practice [4], but for many reasons, this is
not always the case. In COPPADIS-2015, we will
exhaustively evaluate different non-motor features
(NMSS, PDSS,VAS-Pain,VAFS, MMSE, PD-CRS, BDI-II,
NPI, QUIP-RS) in a large population of PD patients. We
will also compare these features with a control group
and analyze their evolution with disease progression.
Finally, we will try to identify related (cross-sectional
assessment) and predictive (prospective follow-up) fac-
tors for the development of different non-motor symp-
toms. For example, factors related to mild cognitive
impairment at baseline and risk factors that could
predict the chance of mild cognitive impairment pro-
gressing to dementia will be identified [36]. We will also
compare non-motor symptoms (and other features of
the disease) and disease progression in patients with
different phenotypes and motor laterality asymmetry.
Moreover, we will try to determine if non-motor
symptoms (NMSS) predict acute hospitalization in PD
patients [37].
At present we have no cure for PD. We use different
therapies to improve patient symptoms, health status,
degree of autonomy and QoL. The key is to understand
what factors affect QoL (depression, pain, motor compli-
cations, etc.), given that interventions will be based on
these factors. Moreover, the role of the patient’s primary
caregiver is also very important because PD is a neuro-
degenerative disorder and the patient will become
increasingly dependent. We will need to determine
Table 3 Working Plan Summary
Assessments Baseline 12 m 24 m 36 m 48 m 60 m
Inclusion/exclusion criteria P; C
Hoehn & Yahr P P P P P P
UPDRS-III and UPDRS-IV P P P P P P
MMSE P; C P; C P; C P; C
PD-CRS P; C P; C P; C P; C
Puzzle test P; C P; C P; C P; C
NMSS P; C P P; C P P; C P; C
BDI-II P; pC; C P; pC; C P; pC; C P; pC; C
QUIP-RS P; C P; C P; C P; C
PDSS P; C P; C P; C P; C
NPI P; C P; C P; C P; C
VAS-Pain and VAFS P; C P; C P; C P; C
FOGQ P; C P; C P; C P; C
ADLS P; C P P; C P P; C P; C
PDQ-39SI P; C P; C P; C P; C
PQ-10 P; pC; C P; pC; C P; pC; C P; pC; C
EUROHIS-QOL 8 item index P; pC; C P; pC; C P; pC; C P; pC; C
ZCBI pC pC pC pC
CSI pC pC pC pC
Samples-serum markers P; C P; C
Samples-genetic studies P; C
Head MRI P; C P; C
ADLS Schwab & England activities of daily living scale, BDI beck depression inventory, C control, CSI caregiver strain index, EUROHIS-QOL European health
interview survey-quality of life, FOGQ freezing of gait questionnaire, m month, MMSE mini mental state examination, MRI magnetic resonance imaging,
NMSS non-motor symptoms scale, NPI neuropsychiatric inventory, P patient, pC primary caregiver, PD-CRS parkinson’s disease cognitive rating scale, PDQ-39SI 39-item
parkinson’s disease quality of life questionnaire summary index, PDSS parkinson’s disease sleep scale, QUIP-RS questionnaire for impulsive-compulsive disorders in parkinson’s
disease-rating scale, UPDRS unified parkinson’s disease rating scale, VAFS visual analog fatigue scale, VAS-Pain visual analog scale-pain, ZCBI zarit caregiver burden inventory
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which factors cause caregivers’ stress and increase their
burden in order to carry out an early intervention, since
caregiver burden generates poor care and, in the long
term, often leads to the patient’s institutionalization [7].
In this regard, it has been observed that patient QoL is
correlated with the caregiver’s status, and interventions
targeted at improving caregiver burden to also improve
the patient’s QoL have been suggested [38]. Although
there are several studies focused on factors related to
caregiver burden [39–41], there is no information about
caregiver strain changes during disease progression. In
COPPADIS-2015 we will analyze changes in QoL, mood
and burden experimented by principal caregivers and we
will attempt to correlate these with changes in different
aspects of the disease (motor symptoms, mood, cogni-
tion, behavior, other non-motor symptoms, etc.) ob-
served in patients.
A top priority at present in PD is to identify a
diagnostic and prognostic biomarker [42, 43]. In
COPPADIS-2015, different molecular markers in
blood will be evaluated (S-100b protein, TNF-ɑ, IL-1,
IL-2, IL-6, vitamin B12, methylmalonic acid, homo-
cysteine, uric acid, C-reactive protein, ferritin and
iron) [44–57], and genetic studies (DNA and RNA)
[58], and cranial MRI (MTAi, volumetry and tracto-
graphy) [30, 59–65] will be performed in a subgroup
of patients and controls. We will try to identify
markers with diagnostic and/or prognostic value,
either alone or in combination (clinical and/or para-
clinical). For example, we will analyze the role of
serum S-100b protein and uric acid as possible prog-
nostic biomarkers [44–46, 56], the relationship
between serum levels of TNF-ɑ, IL-1, IL-2, IL-6 and
C-reactive protein and different non-motor symptoms
[47–51], or the sensitivity and specificity of a simple
puzzle test as a cognitive impairment screening test.
Moreover, biomarkers included in this project have
some of the characteristics needed in an ideal marker:
fast and affordable to obtain; available; repeatable; and
safe [66, 67]. Finally, in the future, other molecular
biomarkers could be analyzed from stored blood sam-
ples and other complementary studies could be done.
Moreover, creation of a brain bank (COPPADIS Brain
Donation Program) from patients included in this pro-
ject is being developed.
Therefore, well-designed, longitudinal prospective
studies must be conducted to identify a biomarker of
linear progression and also to understand the natural
progression of PD. Today, we still do not know what
relationship exists between the progression of motor
symptoms and non-motor symptoms in the long term.
Different longitudinal studies with prospective follow-
up of patients have provided an understanding of the
development of motor complications and their
relationship with the type of symptomatic therapy
initially used [68–70], cognitive impairment and/or
dementia [71–74], the course following a given inter-
vention (e.g., deep brain stimulation) [75, 76] or other
data on the course of the disease [77–86]. There are
other promising studies currently underway with a
fundamental objective of identifying a disease progres-
sion biomarker [87]. Nevertheless, many of the studies
have significant limitations, such as an insufficient
sample size and follow-up, significant losses to follow-
up, limitations in the recruitment or origin of the sam-
ple and performance of analyses not specifically
allowed for in the design. As seen for other neurode-
generative diseases like Huntington’s disease [88], the
most beneficial study model for achieving relevant
advances in the understanding of PD is likely to be a
study that includes a baseline cross-sectional assess-
ment of patients (with a control group) with analysis
of multiple variables (clinical and complementary tests;
for example, serum molecular markers, other biological
samples like cerebrospinal fluid, saliva or skin, structural
neuroimaging, functional neuroimaging, ophthalmological
studies, neurophysiological tests, etc.) followed by a subse-
quent prospective follow-up (ideally over a long period of
follow-up and without losses of cases) of the population
studied with multiple periodic analyses that would make it
possible to compare the course of the different variables
analyzed. These features are all covered by the described
project, COPPADIS-2015. Unlike the PPMI Study, PD
patients at all Hoenh & Yahr stages who meet the selection
criteria and not only early patients will be included in the
COPPADIS Study. That’s because we focused firstly on
studying very exhaustively a large population of PD
patients from different areas of Spain analyzing the
relationship between different variables according to
cross-sectional study methodology. Changes observed in
different variables during the follow-up will be ad-
justed and interestingly, different groups of subjects
according to disease duration, motor stage or to have
motor complications at baseline could be defined to
compare evolution. Some original aspects in COPPA-
DIS are to include the caregivers (the principal
caregiver of the patient was also included in a previous
Spanish Study, the ELEP Study –Estudio Longitudinal
de pacientes con Enfermedad de Parkinson/Longitu-
dinal Parkinson’s Disease Patient Study [89] –), to
study the incidence and predictors of acute
hospitalization and to analyze the value of the MTAi.
Furthermore, as it was mentioned, we are working to
develop a COPPADIS Donation Brain Program. In-
deed, the long-term goal is to design a Spanish PD
patients clinical-pathological registry (with the inclu-
sion of early new patients) with long-term monitoring
and implementation of many additional tests.
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In conclusion, COPPADIS-2015 is a challenging and
original initiative. We hope that this project will provide
important information regarding the natural history of
PD, including changes in motor and non-motor symp-
toms, QoL and caregiver burden over time, and the
value of various biomarkers.
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